Erratum: TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS (Proceedings of the National Academy of Sciences of the United States of America (2016) 113 (E884–E893) DOI: 10.1073/pnas.1525639113);TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 7, 2016, Pages E884-E893

  Wang, Ying ^a   Su, Lijing ^a   Morin, Matthew D ^b   Jones, Brian T ^b   Whitby, Landon R ^b   Surakattula, Murali M R P ^b   Huang, Hua ^b   Shi, Hexin ^a   Choi, Jin Huk ^a   Wang, Kuan Wen ^a   Moresco, Eva Marie Y ^a   Berger, Michael ^b,c   Zhan, Xiaoming ^a   Zhang, Hong ^a   Boger, Dale L ^b   Beutler, Bruce ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Crystal structure; Innate immunity; Neoseptins; Peptidomimetic compounds; Proinflammatory response

Indexed keywords

BETA INTERFERON; CD14 ANTIGEN; I KAPPA B; I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 6; LIPID A; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NEOSEPTIN 1; NEOSEPTIN 3; PEPTIDOMIMETIC AGENT; PHOSPHOTRANSFERASE; PROTEIN MD 2; STRESS ACTIVATED PROTEIN KINASE; TANK BINDING KINASE 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LY96 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; INNATE IMMUNITY; MACROPHAGE CULTURE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; X RAY CRYSTALLOGRAPHY; AGONISTS; ANIMAL; C57BL MOUSE; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PEPTIDOMIMETICS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84958818205     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.2106360118     Document Type: Erratum

References (40)

1. Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol 11(5):373-384.
2. Uematsu S, Akira S (2008) Toll-like receptors and innate immunity. Handbook of Experimewntal Pharmacology, eds Bauer S, Hartmann G (Springer, Berlin), Vol. 183, pp 1-20.
3. Roelofs MF, et al. (2006) Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 176(11):7021-7027.
4. Yu M, et al. (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26(2):174-179.
5. Vabulas RM, et al. (2002) HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 277(17):15107-15112.
6. Vabulas RM, et al. (2002) The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 277(23):20847-20853.
7. Vabulas RM, et al. (2001) Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 276(33):31332-31339.
8. Smiley ST, King JA, Hancock WW (2001) Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 167(5):2887-2894.
9. Termeer C, et al. (2002) Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med 195(1):99-111.
10. Zhang P, Cox CJ, Alvarez KM, Cunningham MW (2009) Cutting edge: Cardiac myosin activates innate immune responses through TLRs. J Immunol 183(1): 27-31.
11. Kim HS, et al. (2007) Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity 27(2):321-333.
12. Schaefer L, et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115(8): 2223-2233.
13. Vogl T, et al. (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13(9):1042-1049.
14. Biragyn A, et al. (2002) Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 298(5595):1025-1029.
15. Johnson GB, Brunn GJ, Kodaira Y, Platt JL (2002) Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168(10):5233-5239.
16. Midwood K, et al. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15(7): 774-780.
17. Walton KA, et al. (2003) Receptors involved in the oxidized 1-palmitoyl-2-arachidonoylsn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Tolllike receptor 4 and a glycosylphosphatidylinositol-anchored protein. J Biol Chem 278(32):29661-29666.
18. Okamura Y, et al. (2001) The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem 276(13):10229-10233.
19. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 204: 27-42.
20. Whitby LR, Boger DL (2012) Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc Chem Res 45(10):1698-1709.
21. Saitoh S, et al. (2004) Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. Int Immunol 16(7):961-969.
22. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR (1991) Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 266(29):19490-19498.
23. Rizo J, Chen X, Araç D (2006) Unraveling the mechanisms of synaptotagmin and SNARE function in neurotransmitter release. Trends Cell Biol 16(7):339-350.
24. Park BS, et al. (2009) The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458(7242):1191-1195.
25. Ohto U, Fukase K, Miyake K, Shimizu T (2012) Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2. Proc Natl Acad Sci USA 109(19):7421-7426.
26. Ohto U, Fukase K, Miyake K, Satow Y (2007) Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 316(5831):1632-1634.
27. Kim JI, et al. (2005) Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 280(12):11347-11351.
28. Jiang Q, Akashi S, Miyake K, Petty HR (2000) Lipopolysaccharide induces physical proximity between CD14 and toll-like receptor 4 (TLR4) prior to nuclear translocation of NF-kappa B. J Immunol 165(7):3541-3544.
29. da Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ (2001) Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2. J Biol Chem 276(24):21129-21135.
30. Zanoni I, et al. (2011) CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 147(4):868-880.
31. Rajaiah R, Perkins DJ, Ireland DD, Vogel SN (2015) CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance. Proc Natl Acad Sci USA 112(27):8391-8396.
32. Hayashi T, et al. (2014) Novel synthetic toll-like receptor 4/MD2 ligands attenuate sterile inflammation. J Pharmacol Exp Ther 350(2):330-340.
33. Chan M, et al. (2013) Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J Med Chem 56(11):4206-4223.
34. Beutler B (2007) Neo-ligands for innate immune receptors and the etiology of sterile inflammatory disease. Immunol Rev 220(1):113-128.
35. Bianchi ME (2007) DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 81(1):1-5.
36. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M (2006) HKL-3000: The integration of data reduction and structure solution-from diffraction images to an initial model in minutes. Acta Crystallogr D Biol Crystallogr 62(Pt 8):859-866.
37. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61(Pt 4):458-464.
38. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-2132.
39. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3): 240-255.
40. Shaginian A, et al. (2009) Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions. J Am Chem Soc 131(15):5564-5572.